FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
WEBMay 5, 2021 · KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for …
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEBSep 15, 2024 · MRK. At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBJun 17, 2024 · KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Approval marks the third FDA-approved indication for KEYTRUDA in endometrial carcinoma and the 40 th indication for KEYTRUDA in the US
Merck's Keytruda Secures First FDA-Approval For Rare Form …
WEBSep 18, 2024 · Wednesday, the FDA approved Merck & Co Inc’s (NYSE: MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with...
FDA approves pembrolizumab with chemotherapy for primary …
WEBOn June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with...
Merck wins first FDA approval for Keytruda as a treatment for ...
WEBSep 18, 2024 · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer...
FDA approves pembrolizumab combination for the first-line …
WEBOn October 13,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent,...
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
Merck gets a ‘surprise’ win for Keytruda in early lung cancer
WEBJan 27, 2023 · The Food and Drug Administration has cleared Merck & Co.’s immunotherapy Keytruda to treat early cases of lung cancer despite mixed results in the main study supporting its application. The regulator on Thursday approved Keytruda as an “adjuvant” treatment following chemotherapy and surgical removal of …
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBOct 13, 2021 · KENILWORTH, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or me...
Skip to content